Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Chiome Bioscience Inc. (4583) Price & Analysis

4583 Stock Chart & Stats

¥89.00-¥3.00(-3.26%)
At close: 4:00 PM EDT
JPY 75JPY 1003 Aug17 Aug31 Aug14 Sep28 Sep13 Oct26 Oct
Day’s Range
JPY 88.00 - JPY 93.00
52-Week Range
JPY 65.00 - JPY 136.00
Previous Close
JPY 92.00
Volume
5.12M
Average Volume (3M)
803.93K
Market Cap
JPY 7.29B
Enterprise Value
JPY 4.67B
Total Cash (Recent Filing)
JPY 1.37B
Total Debt (Recent Filing)
JPY 67.50M
Price to Earnings (P/E)
―
Beta
0.58
Next Earnings
Nov 10, 2026
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Modest Leverage

Modest leverage gives Chiome greater financial flexibility than a highly indebted biotechnology company. Lower debt obligations can reduce pressure on cash resources and preserve room for research investment, although this benefit depends on containing ongoing losses and cash use.

Solid Gross Margin

A consistently solid gross margin indicates that the company’s underlying activities can retain a meaningful share of revenue before operating expenses. If revenue stabilizes and research spending becomes more productive, this margin base could support eventual operating leverage.

Historical Loss Narrowing

The earlier narrowing of losses shows that Chiome has demonstrated some capacity to improve its cost and earnings profile from prior levels. This is not yet a sustained turnaround, but it provides evidence that profitability may improve if development progress and revenue quality strengthen.

Bears Say

Revenue Decline And Volatility

Volatile and declining revenue makes it harder for Chiome to build a dependable funding base for oncology research and development. The 2025 contraction after two years of growth suggests that commercial scale remains unproven and that future investment may rely on uncertain revenue recovery.

Deep Unprofitability

Very large losses relative to revenue indicate that Chiome has not yet converted its biotechnology research activities into an economically sustainable operation. Persistent unprofitability can erode equity over time and limits the company’s ability to fund development internally.

Persistent Cash Burn

Ongoing negative operating and free cash flow shows that accounting losses are translating into real cash outflows rather than being mainly non-cash. If this pattern persists, Chiome will face continuing funding pressure while it finances research and development activities.

Chiome Bioscience Inc. News

4583 FAQ

What was Chiome Bioscience Inc.’s price range in the past 12 months?
Chiome Bioscience Inc. lowest stock price was ¥65.00 and its highest was ¥136.00 in the past 12 months.
What is Chiome Bioscience Inc.’s market cap?
Chiome Bioscience Inc.’s market cap is ¥7.29B.
When is Chiome Bioscience Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Chiome Bioscience Inc.’s earnings last quarter?
Chiome Bioscience Inc. released its earnings results on Aug 13, 2026. The company reported -¥3.31 earnings per share for the quarter.
Is Chiome Bioscience Inc. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Chiome Bioscience Inc. pay dividends?
Chiome Bioscience Inc. does not currently pay dividends.
What is Chiome Bioscience Inc.’s EPS estimate?
Chiome Bioscience Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chiome Bioscience Inc. have?
Chiome Bioscience Inc. has 81,863,700 shares outstanding.
What happened to Chiome Bioscience Inc.’s price movement after its last earnings report?
Chiome Bioscience Inc. reported an EPS of -¥3.31 in its last earnings report. Following the earnings report the stock price went up 2.74%.
Which hedge fund is a major shareholder of Chiome Bioscience Inc.?
Currently, no hedge funds are holding shares in JP:4583
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology